

14 July 2025

Solvonis Therapeutics plc
("Solvonis" or the "Company")

Solvonis Chair Dennis Purcell to speak at Lucid Capital Markets biotech leadership event.

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders is pleased to announce that its Chairman, Dennis Purcell, will participate in an exclusive investor event hosted by Lucid Capital Markets on Thursday, 17 July 2025 at 2:00pm ET.

The event, moderated by Elemer Piros, PhD, Managing Director and Senior Biotech Analyst at Lucid Capital Markets, features a panel discussion with three of the most influential figures in global biopharma: Dennis Purcell (Chair, Solvonis; Founder, Aisling Capital), Stelios Papadopoulos (Chair, Exelixis), and Jeremy Levin (Chair and CEO, Ovid Therapeutics).

The session will explore leadership, innovation, and strategic capital deployment across the biotechnology sector.

Dennis Purcell brings more than 30 years of experience in life sciences investment, having deployed over 15 billion in more than 200 companies through Aisling Capital. His participation in this panel underscores the strength of strategic leadership at Solvonis as the Company advances its AI-enabled CNS drug discovery platform.

Event details:

Date: Thursday, 17 July 2025
Time: 2:00pm ET / 7:00pm BST
Registration link: <https://lnkd.in/eq5pWiFn>

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds targeting high-burden neuropsychiatric conditions with significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD programme leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on a proprietary CNS compound library, with initial focus on depression and stimulant use disorders. This initiative expands the Company's R&D pipeline into earlier-stage innovation while maintaining strategic focus on comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGPUWCMUPAGBW